Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP
Alessandro Busca, Jon Salmanton‐García, Paolo Corradini, et al.
Blood Advances (2021) Vol. 6, Iss. 7, pp. 2427-2433
Open Access | Times Cited: 65

Showing 1-25 of 65 citing articles:

Long-term outcomes following CAR T cell therapy: what we know so far
Kathryn M. Cappell, James N. Kochenderfer
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 6, pp. 359-371
Open Access | Times Cited: 646
Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy
Kitsada Wudhikarn, Miguel‐Angel Perales
Bone Marrow Transplantation (2022) Vol. 57, Iss. 10, pp. 1477-1488
Open Access | Times Cited: 80
A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy
David M. Cordas dos Santos, Tobias Tix, Roni Shouval, et al.
Nature Medicine (2024) Vol. 30, Iss. 9, pp. 2667-2678
Open Access | Times Cited: 63
Chimeric antigen receptor T cell therapy for autoimmune disease
James Chung, Jennifer N. Brudno, Dominic Borie, et al.
Nature reviews. Immunology (2024)
Closed Access | Times Cited: 30
Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians
Eleftheria Kampouri, Carla S. Walti, Jordan Gauthier, et al.
Expert Review of Hematology (2022) Vol. 15, Iss. 4, pp. 305-320
Closed Access | Times Cited: 52
CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges
Matthew Rendo, Jacinth Joseph, Liem Phan, et al.
Blood and Lymphatic Cancer Targets and Therapy (2022) Vol. Volume 12, pp. 119-136
Open Access | Times Cited: 46
Vaccine schedule recommendations and updates for patients with hematologic malignancy post‐hematopoietic cell transplant or CAR T‐cell therapy
Gemma Reynolds, Victoria Hall, Benjamin W. Teh
Transplant Infectious Disease (2023) Vol. 25, Iss. S1
Open Access | Times Cited: 28
Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management
Mariam Markouli, Fauzia Ullah, Serhan Ünlü, et al.
Current Oncology (2023) Vol. 30, Iss. 7, pp. 6330-6352
Open Access | Times Cited: 23
Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022
Jon Salmanton‐García, Francesco Marchesi, Francesca Farina, et al.
EClinicalMedicine (2024) Vol. 71, pp. 102553-102553
Open Access | Times Cited: 12
Vaccine-induced T-cell responses against SARS-CoV-2 and its Omicron variant in patients with B cell–depleted lymphoma after CART therapy
Djordje Atanackovic, Tim Luetkens, Destiny Omili, et al.
Blood (2022) Vol. 140, Iss. 2, pp. 152-156
Open Access | Times Cited: 29
Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
Jaap A. van Doesum, Jon Salmanton‐García, Francesco Marchesi, et al.
Blood Advances (2023) Vol. 7, Iss. 11, pp. 2645-2655
Open Access | Times Cited: 21
Serologic response and safety of COVID-19 vaccination in HSCT or CAR T-cell recipients: a systematic review and meta-analysis
Chenghao Ge, Kelei Du, Mingjie Luo, et al.
Experimental Hematology and Oncology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 25
SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report
Kevin O. McNerney, Rebecca M. Richards, Paibel Aguayo‐Hiraldo, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 1, pp. e005957-e005957
Open Access | Times Cited: 14
Current outcomes of SARS-CoV-2 Omicron variant infection in high-risk haematological patients treated early with antivirals
Tommaso Francesco Aiello, Pedro Puerta‐Alcalde, Mariana Chumbita, et al.
Journal of Antimicrobial Chemotherapy (2023) Vol. 78, Iss. 6, pp. 1454-1459
Open Access | Times Cited: 12
Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings
Giuseppe Rossi, Jon Salmanton‐García, Chiara Cattaneo, et al.
International Journal of Infectious Diseases (2023) Vol. 137, pp. 98-110
Open Access | Times Cited: 11
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey
Tobias Lahmer, Jon Salmanton‐García, Francesco Marchesi, et al.
Infection (2024) Vol. 52, Iss. 3, pp. 1125-1141
Open Access | Times Cited: 4
Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group
Anne M. Spanjaart, Per Ljungman, Gloria Tridello, et al.
Leukemia (2024) Vol. 38, Iss. 9, pp. 1985-1991
Open Access | Times Cited: 4
Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAFV600E-mutant metastatic colorectal carcinoma
K. Connolly, Daniel Brungs, E. Szeto, et al.
Current Oncology (2013) Vol. 21, Iss. 1, pp. 151-151
Open Access | Times Cited: 41
Immune response to three doses of mRNA SARS-CoV-2 vaccines in CD19-targeted chimeric antigen receptor T cell immunotherapy recipients
Pierre Sesques, Emmanuel Bachy, Emmanuelle Ferrant, et al.
Cancer Cell (2022) Vol. 40, Iss. 3, pp. 236-237
Open Access | Times Cited: 19
Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era
Tingting Zhang, Weiwei Tian, Shuang Wei, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 10
COVID‐19 after hematopoietic cell transplantation and chimeric antigen receptor (CAR)‐T‐cell therapy
Eleftheria Kampouri, Joshua A. Hill, M. Veronica Dioverti
Transplant Infectious Disease (2023) Vol. 25, Iss. S1
Closed Access | Times Cited: 10
The Efficacy of Chimeric Antigen Therapy in Viral Infectious Diseases: A Systematic Review of Randomized Controlled Trials
Hossein Hatami, Elnaz Ataei, Mohammad Javad Nasiri, et al.
Turkish Journal of Immunology (2025) Vol. 12, Iss. 3, pp. 84-91
Open Access
Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With Aggressive B-Cell Non-Hodgkin Lymphoma
Lina Camacho-Arteaga, Gloria Iacoboni, Mi Kwon, et al.
JAMA Network Open (2025) Vol. 8, Iss. 2, pp. e2461683-e2461683
Open Access
Risk of Severe COVID-19 in Four Immunocompromised Populations: A French Expert Perspective
Paul Loubet, Iliès Benotmane, Slim Fourati, et al.
Infectious Diseases and Therapy (2025)
Open Access
Infectious complications of chimeric antigen receptor (CAR) T-cell therapies
Juan Gea‐Banacloche
Seminars in Hematology (2023) Vol. 60, Iss. 1, pp. 52-58
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top